ARVNARVN
US • —
$8.31
P/E
—
PEG
—
FCF Yield
—
Rev Growth YoY
-79.1% YoY
Gross Margin
—
Health Score
2/10
D/E Ratio
—
Confidence
LOW
Business Snapshot
Arvinas operates in the biotechnology industry, focusing on developing protein degradation therapies, including its lead candidate for prostate cancer. It competes in the targeted oncology space as a clinical-stage challenger, with no approved products generating revenue. The company is a micro-cap biotech with no current product revenue, indicated by a net margin flagged at -247.5%, reflecting its pre-commercial, R&D-intensive stage. A defining characteristic is its novel PROTAC platform for degrading disease-causing proteins, which represents a high-risk, high-reward scientific approach. The company relies on partnerships and capital markets for funding given its lack of commercial revenue.
Financial Health
The net margin is flagged at -247.5% but is noted as potentially distorted by a data error or extreme non-operating event; as a pre-revenue biotech, the company is deeply unprofitable from ongoing operations. The balance sheet shows no debt (debt/equity of 0.0x) and a strong liquidity position with a current ratio of 4.92x, providing a significant cash runway for operations...
Risk Assessment
- EARNINGS QUALITY — The company has beat earnings estimates in 3 of the last 4 quarters, but this is a fragile metric for a pre-revenue biotech where 'earnings' are driven by managed guidance and non-cash items.
- REVENUE DECELERATION — Revenue growth of -79.1% YoY indicates a severe decline in top-line collaboration revenue, highlighting a lack of sustainable recurring income.
- FCF / CASH BURN — Free cash flow is negative and unavailable for calculation, confirming the company is burning through its cash reserves to fund research and operations.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- DATA COMPLETENESS — A fundamental data vacuum exists as core metrics like P/E ratio, revenue, and free cash flow are unavailable, significantly increasing investment uncertainty and risk....
The net margin is flagged at -247.5% but is noted as potentially distorted by a data error or extreme non-operating event; as a pre-revenue biotech, the company is deeply unprofitable from ongoing operations. The balance sheet shows no debt (debt/equity of 0.0x) and a strong liquidity position with a current ratio of 4.92x, providing a significant cash runway for operations. Return on equity is deeply negative at -44.4%, as the company burns through shareholder equity to fund research without generating profits. Free cash flow is negative and unavailable for calculation, indicating the company is a cash-burning entity requiring ongoing external financing. Overall, financial health is fragile and characteristic of a clinical-stage biotech that is entirely dependent on its pipeline's success and capital markets access for survival.
- EARNINGS QUALITY — The company has beat earnings estimates in 3 of the last 4 quarters, but this is a fragile metric for a pre-revenue biotech where 'earnings' are driven by managed guidance and non-cash items. - REVENUE DECELERATION — Revenue growth of -79.1% YoY indicates a severe decline in top-line collaboration revenue, highlighting a lack of sustainable recurring income. - FCF / CASH BURN — Free cash flow is negative and unavailable for calculation, confirming the company is burning through its cash reserves to fund research and operations. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - DATA COMPLETENESS — A fundamental data vacuum exists as core metrics like P/E ratio, revenue, and free cash flow are unavailable, significantly increasing investment uncertainty and risk.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives